MDT
88.44
-1.53%↓
VEEV
227.74
-1.64%↓
A
113.65
-2.76%↓
HQY
87.08
-1.46%↓
PDCO
31.26
0%↓
MDT
88.44
-1.53%↓
VEEV
227.74
-1.64%↓
A
113.65
-2.76%↓
HQY
87.08
-1.46%↓
PDCO
31.26
0%↓
MDT
88.44
-1.53%↓
VEEV
227.74
-1.64%↓
A
113.65
-2.76%↓
HQY
87.08
-1.46%↓
PDCO
31.26
0%↓
MDT
88.44
-1.53%↓
VEEV
227.74
-1.64%↓
A
113.65
-2.76%↓
HQY
87.08
-1.46%↓
PDCO
31.26
0%↓
MDT
88.44
-1.53%↓
VEEV
227.74
-1.64%↓
A
113.65
-2.76%↓
HQY
87.08
-1.46%↓
PDCO
31.26
0%↓
24h
Praegune
Min
267.68
Max
281.38
Sissetulek | -31M -152M |
---|---|
Müük | 126M 1.1B |
Kasumimarginaal | -13.467 |
Soovitused | Tugev "osta" hinnang |
---|---|
12 kuu keskmine prognoos | +17.92% upside |
Järgmine tulemuste avaldamine | 7. mai 2025 |
---|
Turukapital | 22B |
---|---|
Eelmine avamishind | 270.47 |
Eelmine sulgemishind | 270.1 |
By Acuity
50%
50%
173 / 386 Pingereas Healthcare
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
29. jaan 2025, 15:59 UTC
ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene
DJ
Loe
27. nov 2024, 15:22 UTC
BeiGene Shares Up on EU Approval for Gastric, Esophageal Cancer Treatment
DJ
Loe
21. nov 2024, 14:45 UTC
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
DJ
Loe
22. okt 2024, 18:39 UTC
Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment
DJ
Loe
23. apr 2024, 14:58 UTC
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment
DJ
Loe
27. veebr 2025, 11:07 UTC
BeiGene Sees 2025 Rev $4.9B-$5.3B >ONC
DJ
Loe
27. veebr 2025, 11:06 UTC
BeiGene 4Q Global BRUKINSA Rev of $828M >ONC
DJ
Loe
27. veebr 2025, 11:06 UTC
BeiGene 4Q Loss/Shr 11c >ONC
DJ
Loe
27. veebr 2025, 11:06 UTC
BeiGene 4Q Rev $1.13B >ONC
DJ
Loe
12. nov 2024, 11:01 UTC
BeiGene 3Q Loss/Shr 9c >BGNE
DJ
Loe
12. nov 2024, 11:01 UTC
BeiGene 3Q Rev $1B >BGNE
DJ
Loe
7. aug 2024, 10:05 UTC
BeiGene 2Q Loss/Shr $1.15 >BGNE
DJ
Loe
7. aug 2024, 10:04 UTC
BeiGene 2Q Rev $929M >BGNE
DJ
Loe
8. mai 2024, 10:02 UTC
BeiGene 1Q Loss/Shr 19c >BGNE
DJ
Loe
8. mai 2024, 10:01 UTC
BeiGene 1Q Loss $251.2M >BGNE
DJ
Loe
8. mai 2024, 10:01 UTC
BeiGene 1Q Rev $752M >BGNE
DJ
Loe
Hinnamuutus
By TipRanks
12 kuu keskmine prognoos
Keskmine 320.95 USD 17.92%
Kõrge 359.47 USD
Madal 259 USD
Põhineb 12 Wall Streeti analüütiku instrumendi BeiGene Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.
By TipRanks
Tugev "osta" hinnang
12 ratings
11
Osta
1
Hoia
0
Müü
Põhineb 12 analüütiku instrumendi BeiGene Ltd ADR aktsia reitingul - viimase 3 kuu andmed.
By Acuity
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Keskmine
Müügi- ja halduskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Ärikasum
$